Aviragen Therapeutics Inc Share Price Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-22 | Daniel P. Houle Issues an Investor Presentation | CI |
| 06-16 | Vaxart Provides Information to Shareholders | CI |
| Market Cap | 129M 113M 104M 97.39M 183M 12.2B 184M 1.24B 482M 6B 485M 474M 20.84B | P/E 2026 * |
1.84x | P/E 2027 * | -0.55x |
|---|---|---|---|---|---|
| Enterprise Value | 129M 113M 104M 97.39M 183M 12.2B 184M 1.24B 482M 6B 485M 474M 20.84B | EV / Sales 2026 * |
0.36x | EV / Sales 2027 * | - |
| Free-Float |
98.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 17/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 29/02/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 18/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 20/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 03/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 31/03/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.40% | +5.74% | +71.50% | +120.04% | 56.65B | |
| +4.00% | +7.51% | +63.67% | +68.77% | 47.49B | |
| -0.77% | -0.67% | -15.34% | -15.95% | 22.81B | |
| +2.93% | +1.17% | -3.97% | +384.78% | 21.37B | |
| +1.30% | +3.73% | +27.10% | -17.51% | 16.12B | |
| +1.81% | +8.48% | +24.76% | -35.52% | 15.56B | |
| -1.08% | -3.11% | +27.20% | +158.30% | 12.91B | |
| +3.30% | +15.02% | +133.24% | +273.89% | 12.86B | |
| +1.43% | -6.44% | +21.49% | - | 11.67B | |
| Average | +1.47% | +2.16% | +38.85% | +117.10% | 24.16B | |
| Weighted average by Cap. | +1.61% | +3.27% | +44.96% | +110.11% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 356M 311M 288M 268M 504M 33.63B 508M 3.42B 1.33B 16.54B 1.34B 1.31B 57.45B | - |
| Net income | 116M 101M 93.76M 87.51M 164M 10.96B 165M 1.11B 434M 5.39B 436M 426M 18.72B | -284M -248M -230M -214M -402M -26.84B -405M -2.73B -1.06B -13.2B -1.07B -1.04B -45.84B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
